Prostate Cancer (PCa) is statistically one of the most common malignant neoplasms among men. Existing screening programs led to the increased detectability of the tumor in the early clinical stages. Scientifically proven, effective and recommended by the European Association of Urology treatment of PCa in stages confined to the prostate gland is a radical prostatectomy or radiotherapy. Methods yield similar good results, but are fraught with early and late complications. For this reason, the search for alternative solutions to the above methods of treating prostate cancer in a low stage has started. One of such alternative approaches is developed over 15 years HIFU. However, as with any new treatment method in surgery, its efficacy and safety have to be confirmed in numerous scientific studies. One of such studies was conducted by the doctors from the Institut Montsouris in Paris.
Prostate cancer is the most common carcinoma of urogenital organs. It is the second most common cancer occurring among the whole male population. Annually there are 9000 new cases diagnosed and a rising tendency has been observed throughout the last 3 decades. Despite of a wide access to radio- and chemotherapy as well as various hormonal therapies and surgical methods, this neoplasm causes around 8% of all deaths in Poland every year. Scientists from Houston Methodist Hospital in Texas have come up with a new method of prostate cancer treatment which is both effective and safe for the patients. It is based on the modification of cancer cell genes with the use of a virus which causes the immune system of a patient to recognise and attack the infected tumour cells.
Scientists from the University of Southern California have found a new target for prostate cancer drugs – it is recently discovered GPR 158. It has been demonstrated that increased expression of GPR 158 correlates with worse prognosis and hyperproliferation of prostate cancer cells.
A new study of Swedish researchers, recently published in the ‘European Urology’ journal, proposes to introduce a “genetic score” based on the analysis of single nucleotide polymorphisms (SNPs) to identify men at high risk of developing prostate cancer, whose serum PSA concentration is within the limits of 1-3 ng/ml (gray range). In this concrete group of patients a prostate biopsy would be indicated. Read full text »
Can we expect prostate artery embolization (PAE) to become a new breaktrough treatment for benign prostate hyperlpasia (BPH)? A new minimally invasive tretment – PAE, developed and performed by interventional radiologists can become an alternative method for surgery. There is a clinical evidence that this method of BPH treatment can result with prolonged reduction of the symptoms including frequent urinating. Promising results of this approach were recently presented during 39th Annual Scientific Meeting Society of Interventional Radiology. Read full text »
Two studies, recently published in the „Journal of the National Cancer Institute”, shed new light on the relationship between selenium and the risk of prostate cancer. In the first study, U.S. researchers have proven that supplementation of selenium (depending on its initial content in organism) may increase the risk of developing prostate cancer. In the second study, Dutch researchers suggest that the high selenium levels in the body (without supplementation) can have a protective effect. Read full text »
The usage of genetic tests in clinical practice made finding correlation between carrier-state of BRCA1 and BRCA2 genes mutation and increased risk of breast and ovary cancer development possible. Mutations of these genes are also found in men and are considered as a potential cause of prostate cancer. According to a research of Clinical Oncology conducted in Madrid, patients with prostate cancer and with the mutation have to reckon with the aggressive course of the disease.